// App-Quantinova.ai

455 : Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis

Researchers

Presenter

  • A. Shabbir

Principal Investigators

  • A.S. Paller

  • B. Lockshin

  • M.J. Cork

  • M. Morren

  • Y. Kataoka

  • Z. Chen

  • A.B. Rossi

  • Y. Lu

Medical Centers

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

  • Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

  • Georgetown Uni, Rockville, Maryland, United States

  • Sheffield Dermatology Research, University of Sheffield, Sheffield, UK

  • Lausanne University Hospital, Lausanne, Switzerland

  • Osaka Habikino Medical Care Center, Osaka, Japan

  • Sanofi Genzyme, Cambridge, MA, United States

Locations

  • United States

  • United Kingdom

  • Switzerland

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved